Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are used as first-line agents for treating nonsquamous cell lung cancer with EGFR mutation, there are many patients who have to receive these drugs following platinum-based chemotherapy. This study was designed to define whether exposure to cisplatin could affect the sensitivity to EGFR TKIs because conflicting results have been presented. We established sublines that are resistant to cisplatin from EGFR wild-type cells (A549 and H460) and EGFR mutant cells (PC-9 and HCC827). The EGFR-related signals were examined by Western blotting. MTT assay and the trypan blue exclusion method were used for the in vitro study, while tumor size and the SUV of the 18 FDG-PET scans were measured in animal models. The IC 50 value and apoptotic fractions after exposure to EGFR TKIs, such as gefitinib, erlotinib, and BIBW 2992, were almost the same in the cisplatinresistant sublines compared to that of the parent cells. Although the baseline PTEN expression was reduced in the resistant cells, as was indicated in a previous study, the EGFR-related signals similarly responded to the EGFR TKIs. Furthermore, the reduced tumor size and SUV of the 18 FDG-PET of the implanted tumor in nude mice according to erlotinib treatment were not different between the resistant sublines and the parent cells. In conclusion, the acquired resistance to cisplatin did not affect the sensitivity to EGFR TKIs in the EGFR mutant lung cancer cells, and this should abrogate any concerns about the use of EGFR TKIs following platinum-based chemotherapy.
INTRODUCTION
carboplatin-paclitaxel (1). However, there are still many patients who have to receive EGFR TKIs following platinum-based chemotherapy because platinum-based cytoEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as gefitinib and erlotinib toxic chemotherapy is recommended in case of unknown EGFR mutation status or squamous cell lung cancer. in the treatment of non-small cell lung cancer (NSCLC) result in clinical benefits, especially in patient with
One of major concerns is whether the platinum-based first-line chemotherapy would influence the subsequent EGFR TK mutations of G719A on exon 18, a deletion mutation on exon 19, and L858R on exon 21 (1, 2) . Clinresponsiveness of cancer cells to EGFR TKIs. To address this issue, Chin et al. performed a preclinical ical characteristics such as never-smoker, female, adenocarcinoma histology, and Asian heritage also could help study using NSCLC cells with acquired resistance to cisplatin (4). They found that those cells exhibited reduced to select patients responding better, although they are not completely matched with EGFR TK mutations (3) .
sensitivity to erlotinib through downregulation of PTEN, leading to persistent EGFR-independent PI3K/Akt sigCurrently EGFR TKIs are used as first-line agents for treating NSCLC with EGFR mutation after a phase III naling. From these results, they suggested that NSCLC patients with first-line EGFR TKIs might have more trial, open-label study (the IRESSA Pan-Asia Study) demonstrated significantly longer progression-free surfavorable clinical outcomes compared to patients treated with second-line or further EGFR TKIs in terms of vival (PFS) and higher objective response rates (p < 0.0001) among EGFR mutation-positive patients who progression-free interval. However, there has been no report demonstrating that longer progression-free or received gefitinib than among those who received ) were seeded into six-well plates in triplicate, and treated with EGFR TKIs for 72 TKIs, although some recent studies showed the very impressive response rate in patients with EGFR TK h. As the drugs were exhausted from the medium over time, fresh drug-supplemented medium was added every mutations (5). Rather, most studies containing results of comparison between first-line and second-line EGFR 3 days over 10 days. Cells were trypsinized and cell numbers were determined with an ADAM-MC autoTKIs showed no difference in clinical outcomes (6). In addition, there were contradictory preclinical experimatic cell counter (NanoEnTek, Seoul, Korea) according to the manufacturer's instructions. ments showing that chemotherapy-resistant tumor cell lines acquired enhanced sensitivity to EGFR TKIs (7,8).
Our study was performed to answer this controversial Immunoblot Analysis issue of whether the sensitivity to EGFR TKIs would be Proteins from cell lysates were prepared as prereduced by acquisition of resistance to cisplatin, which viously described (10), separated by SDS-PAGE, and has important clinical implication.
then electrotransferred onto Immobilon membranes (Millipore, Billerica, MA, USA). These membranes
MATERIALS AND METHODS
were subsequently probed with specific antibodies for pCell Culture and Reagents EGFR (Tyr1173), EGFR, p-Akt (Ser 473), Akt, p-Erk (Thr202/Tyr204), Erk, PTEN, p27, Bim, and β-actin Four human NSCLC cell lines were used in this were obtained from Santa Cruz Biotechnology (Santa study. A549, H460, and HCC827 cells were purchased Cruz, CA, USA). The secondary antibodies used were from the American Type Culture Collection. PC-9 cells horseradish peroxidase-conjugated antibodies and then were a gift from F. Koizumi and K. Nishio (National the membrane were developed using an ECL kit (AmerCancer Center Hospital, Tokyo, Japan). Cells were culsham Biosciences, Piscataway, NJ, USA). tured in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS), 100 U/ml Apoptosis Assay penicillin, and 100 µg/ml streptomycin (Invitrogen) at 37°C in an atmosphere of 5% CO 2 . BIBW2992 was Apoptosis was quantified using the Annexin V-FITC obtained from Selleck Chemicals Co. Ltd (Houston, TX, apoptosis kit (BD Biosciences, San Diego, CA) in accor-USA). Cisplatin and paclitaxel were purchased from dance with the manufacturer's instructions. Briefly, cells Sigma (St. Louis, MO, USA). The gefitinib, erlotinib, were trypsinized (Invitrogen), pelleted by centrifugation, and gemcitabine were kindly provided by AstraZeneca, and resuspended in Annexin V binding buffer (150 Roche and Lilly, respectively. mmol/L NaCl, 18 mmol/L CaCl 2 , 10 nmol/L HEPES, 5 mmol/L KCl, 1 mmol/L MgCl 2 ). FITC-conjugated
Establishment of the Cisplatin-Resistant Cell Lines
Annexin V (1 µg/ml) and propidium iodide (50 µg/ml) were added to cells and incubated for 30 min at room All cells were exposed to 1 µmol/L (about IC 20 values temperature in the dark. Analyses were done on a of each cell) cisplatin for 48 h in medium containing FACScan (Becton Dickinson, Mountain View, CA). 10% FBS. They were then washed and cultured in drug-
The data were analyzed with CellQuest software free medium until surviving cells were 80% confluent.
(Becton Dickinson). These cells were continuously exposed to increasing concentrations of cisplatin. Cells that were able to grow in 5 µmol/L cisplatin were obtained 8 months after iniXenograft In Vivo Study tial exposure. Cisplatin-resistant cells were designated Female severe combined immunodeficiency (SCID) A549/CR, H460/CR, HCC827/CR, and PC-9/CR, respecmice (18-20 g, 6 weeks old) were purchased from the tively. For all studies, the resistant cells were cultured in Animal Resources Centre. Tumors were grown by drug-free medium for at least 1 week to eliminate the implanting cells (5 × 10 6 ) in Matrigel (BD Biosciences) effects of cisplatin. Two individual clones were isolated into the mouse shoulders. The mouse carried a PC-9 (A549/CR-1 and -2; H460/CR-1 and -2; HCC827/CR-1 xenograft on the left shoulder and a PC-9/CR xenograft and -2; PC-9/CR-1 and -2) from each resistant cell line.
on the right shoulder. Treatment of the three mice per group was started when the tumors had reached a volCell Survival Assays ume of 50-100 mm 3 with vehicle control, erlotinib (100 mg/kg, 5 days a week). Erlotinib were orally adminisFor the MTT assay, cells seeded onto 96-well plates overnight. Each drug was added and then cells were tered. Treatment was stopped after 11 days and mice were followed up for tumor recurrence. For tumor size incubated for 72 h. Cell viabilities were determined using MTT assay as described by Carmichael et al. (9). measurements, the length (L) and width (W) of the tumor were measured with calipers, and tumor volume established cell line models of acquired resistance to cisplatin. We selected four cell lines, including cells with (TV) was calculated as TV = (L × W 2 )/2. Positron emission tomography (PET) scans were done before and wild-type EGFR (A549 and H460) and mutant EGFR (HCC827 and PC-9). Cisplatin-resistant cells were after administration of drugs (0 and 7 days).
established, as described in Materials and Methods. The cisplatin-resistant cell lines are referred to as A549/CR, PET Image Acquisition H460/CR, HCC827/CR, and PC-9/CR, respectively. In 18 F-FDG PET imaging was performed with a dediaddition, two sublines were isolated from each resistant cated small animal PET scanner (MicroPET R4 scancell. All resistant cells showed above fourfold resistance ner, Concorde Microsystems, Knoxville, TN) using LSO to cisplatin (Table 1 , Fig. 1a ). Besides the sensitivity to crystals, 350-750 keV energy window and timing winpaclitaxel in PC-9/CR cells, other resistant cells showed dows of 6 ns. PET imaging was started 60 min after the no cross-resistance against conventional anticancer administration of 7.4 MBq/0.1 ml of 18 F-FDG via tail drugs such as gemcitabine and paclitaxel (Table 1 ). In vein injection. Mice were anesthetized with 2% isofluraddition, all cisplatin-resistant cell lines showed no ane in 100% oxygen (Forane solution; ChoongWae cross-resistance against reversible EGFR TKIs (gefitinib Pharma, Seoul, South Korea) for uptake and scanning.
and erlotinib) and BIBW2992, an irreversible EGFR After position scanning, each mouse was scanned for 20
TKIs (Table 1 , Fig. 1b) . A longer term clonogenic surmin to obtain a static image. The acquired three-dimenvival assay also showed similar results (Fig. 1c) . sional emission list-mode data was reconstructed to temporally framed sinograms using Fourier rebinning (FORE) and ordered subsets expectation maximization
Reduced PTEN Expression Was Commonly Found in Cisplatin-Resistant Cells Without Affecting the (OSEM2D) reconstruction algorithm with four iterations. PET values were first converted to standardized

Capability of EGFR TKIs to Modulate EGFR Akt Signaling and Induce Apoptosis uptake values (SUV) using the MicroPET ASIPro software (Concorde Microsystems). Image visualization and
One study showed that EGFR mutant NSCLC cells analysis were performed using the nonproprietary Amide's with acquired cisplatin resistance reduced erlotinib sena Medical Image Data Examiner (AMIDE) software. sitivity (4). They demonstrated that these results were correlated with reduced PTEN function. Thus, we exam-RESULTS ined the basal level of PTEN as well as EGFR-related Acquisition of Resistance to Cisplatin Did Not Affect molecules. As shown in Figure 2a , the reduction of the Sensitivity to EGFR TKIs PTEN was observed in all cisplatin-resistant cells except for HCC827/CR cells. Nonetheless, all EGFR TKIs To determine whether acquisition of resistance to cisplatin influences the sensitivity to EGFR TKIs, we could modulate EGFR and downstream Akt activity Values are mean IC 50 with SD in parentheses. The drug concentration (µM) is that responsible for 50% growth inhibition as determined in the MTT assay at 72 h. Data represent the mean from at least three independent experiments. dose and time dependently regardless of PTEN expresuptake and tumor size reduction between them. In addition, the growth of cisplatin-resistant tumor resumed at sion in EGFR mutant cells (Fig. 2b, c) . Consistent with this, induction of p27, Bim, and subsequent apoptosis a similar rate to that seen in parental tumor after administration of erlotinib was discontinued. These findings similarly occurred in cisplatin-resistant cells (Fig. 2d) .
suggest that acquisition of resistance to cisplatin has no influence on the efficacy of EGFR TKIs.
Antitumor Effects of Erlotinib Were Also Similar in Cisplatin-Sensitive and Cisplatin-Resistant Tumor Xenografts DISCUSSION
We provided preclinical data suggesting that secondNext, we established PC-9 and PC-9/CR tumor xenografts to confirm in vitro results. The sensitivity to erlotline EGFR TKIs would have comparable efficacy to first-line treatment. EGFR signaling is important for inib was evaluated by 18 F-FDG uptake changes and tumor growth inhibition. In PC-9 and PC-9/CR tumor cancer cell proliferation and survival. Various kinds of cancer cells increased EGFR expression for survival as xenografts, erlotinib treatment led to the reduction of 18 F-FDG uptake and tumor volume (Fig. 3 ). There were a response to cytotoxic chemotherapeutic agents, which made them more susceptible to the inhibition of EGFR no significant differences in the change of The effect of erlotinib in a cisplatin-resistant cell xenograft model. SCID mice carried a PC-9 xenograft on the left shoulder (white arrows) and a PC-9/CR xenograft on the right shoulder (red arrows). Three mice used in each group were treated daily with 100 mg/kg erlotinib for 11 days. (a) PET images of tumors from PC-9 and PC-9/CR tumor-bearing mouse were obtained before (0 day) and after (7 day) erlotinib treatment. The graph shows 18 FDG uptake change on day 7 after the first injection. (b) Length and width of the tumors were measured at days indicated, and tumor volumes were calculated. Bars present mean tumor volume ± SD. signals (8). It was also proved in xenograft animal modresistant cells to EGFR TKIs commonly exhibit persistent Akt activation, although its activation could be els. In addition, Servidei et al. showed that altered signaling of receptor EGFR family, such as overexpression decreased by treatment of drug, as so-called "Akt tail" (12) . Chin et al. found that exposure to cisplatin in PCand constitutive phosphorylation of ErbB2 and ErbB3, altered HER ligand expression and enhanced activation 9 cells resulted in reduction of PTEN contributing to persistent Akt phosphorylation. PTEN loss has been of EGF-triggered EGFR pathway might contribute to increased sensitivity to gefitinib in chemoresistant tumor shown to be involved in EGFR TKIs resistance in some tumor cell lines (13) (14) (15) . In addition, another study cell lines (7). However, because these earlier studies did not use EGFR mutant lung cancer cells, their result showed that PTEN loss contributes to erlotinib resistance in EGFR mutant lung cancer (16) . However, they would not be clinically relevant. Therefore, the study conducted by Chin et al. with lung cancer cells harborsuggested that immediate and constitutive activation of Akt is more effective than PTEN loss to induce erlotinib ing deletion mutation on exon 19 seems to have more clinical implication (4).
resistance. Thus, the modulation of Akt activity plays a key role in determining sensitivity to EGFR TKIs. In our The sensitivity to EGFR TKIs is considered to be mostly dependent on Akt activation (11). Actually, study, PTEN expression was also reduced in resistant
